NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom, Inc." or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom, Inc. investors who were adversely affected by alleged securities fraud between July 26, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/dexcom-inc-lawsuit-s ...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCMNovember 05, 2025 6:17 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=175417&from=3 CLASS PERIOD: July 26, 2024 to Se ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your DexCom investments, you have until December 26, 2025 to request lead plaintiff appointment. Follow the ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In DexCom (DXCM) To Contact Him Directly To Discuss Their Options If you purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Braga ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/dexcom-inc-class-action-lawsuit. ...

Core Viewpoint - A class action lawsuit has been filed against Dexcom, Inc. for allegedly misleading investors about the safety and reliability of its continuous glucose monitoring systems, specifically the G6 and G7 models [1][2]. Allegations - The lawsuit claims that Dexcom made unauthorized material design changes to the G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - It is alleged that Dexcom overstated the enhancements and reliability of the G7 system while downplaying the severity of issues related to adulterated devices [2]. - The complaint suggests that these actions have exposed Dexcom to increased regulatory scrutiny and potential legal repercussions [2]. Impact of Hunterbrook Report - A report published by Hunterbrook on September 18, 2025, highlighted severe health risks associated with the G7 devices, including incidents of hospitalization and death linked to inaccurate glucose readings [3]. - Following the release of this report, Dexcom's stock price dropped by $8.99 per share, or 11.76%, closing at $67.45 on September 19, 2025 [3]. Class Action Participation - Investors who purchased Dexcom securities between July 26, 2024, and September 17, 2025, may be eligible to participate in the class action, with a deadline for lead plaintiff submissions set for December 29, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Company Overview - DexCom manufactures continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7, which were marketed as highly accurate devices [3]. Allegations - The lawsuit alleges that DexCom made unauthorized design changes to the G6 and G7, compromising their accuracy and exposing customers to serious health risks while prioritizing cost reduction over safety [4]. Stock Performance - DexCom's stock experienced notable declines due to revelations about product quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [5]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [6]. - A report published on September 18, 2025, indicated severe safety issues, leading to a nearly 12% decline of $8.99 per share over two trading days [7].

Core Insights - DexCom (DXCM) stock is currently trading within a support range of $55.31 to $61.13, where it has historically bounced back significantly, achieving an average peak return of 66.2% over the past decade [2]. Company Overview - DexCom specializes in continuous glucose monitoring systems, including the next-generation G7 CGM, which is available for use in the U.S. and internationally [4]. - The company has demonstrated a revenue growth rate of 9.3% over the last twelve months (LTM) and an average growth rate of 17.3% over the past three years [5]. - DexCom has a free cash flow margin of nearly 13.3% and an operating margin of 16.0% LTM [5]. Historical Performance - The stock has experienced significant declines during major market downturns, including a drop of nearly 87% during the Global Financial Crisis, 48% in the 2018 correction, and 58% during the inflation spike, as well as a 37% decline during the Covid pandemic [4][5]. - Despite these downturns, the stock has shown resilience and has recovered from past revenue shocks, with the lowest annual revenue growth in the last three years being 9.3% [5]. Valuation Metrics - DexCom stock is currently valued at a price-to-earnings (PE) multiple of 39.9 [5].

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 systems, which compromised their reliability and presented health risks to users [2]. - It is alleged that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to the devices [2]. - The company is accused of exposing itself to increased regulatory scrutiny and potential legal, reputational, and financial harm due to these actions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as a lead plaintiff in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].